EDMONTON, June 13 /CNW/ - Quest PharmaTech Inc. (“Quest” or the “Company”) Quest is pleased to announce that patient enrollment has been completed in the Phase I clinical study of SL017 Topical Gel for the photodynamic therapy of actinic keratosis (AK), with centers in Edmonton and Montreal.
